LSH

Total Revenue (Nine Months): $11.48 million, down from $13.53 million in the previous year. Total Revenue (Third Quarter): $3.18 million, compared to $4.46 million in the third quarter of 2024. Cross-Boundary Freight Solutions Revenue (Nine Months): $10.76 million, down from $13.53 million in the previous year. Cross-Boundary Freight Solutions Revenue (Third Quarter): $3.31 million. Pharmaceutical Distribution Revenue (Nine Months): $715,362. Pharmaceutical Distribution Revenue (Third Quarter): $497,276. Gross Profit (Nine Months): $1.20 million. Gross Profit (Third Quarter): $0.72 million. Operating Expenses (Nine Months): $5.6 million. Operating Expenses (Third Quarter): $1.8 million. Loss from Operations (Nine Months): $4.40 million. Loss from Operations (Third Quarter): $1.10 million. Net Loss (Nine Months): $4.35 million or $0.58 per share. Net Loss (Third Quarter): $1.07 million or $0.14 per share. IPO Proceeds: Approximately $6.75 million raised on July 1, 2024. Convertible Debt Financing: Up to $4.5 million announced in March 2025. Warning! GuruFocus has detected 2 Warning Sign with LSH. Release Date: May 22, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lakeside Holding Ltd (NASDAQ:LSH) has successfully expanded into the pharmaceutical distribution sector, with the acquisition of Huiyu Pharmaceutical contributing $715,362 in revenue for the nine months ended March 31, 2025. The company raised approximately $6.75 million through its initial public offering, providing necessary capital to fuel strategic initiatives. Lakeside Holding Ltd (NASDAQ:LSH) is leveraging its logistics expertise to optimize Huiyu Pharmaceutical's supply chain and distribution network in China, enhancing operational efficiency. The company is actively pursuing new distribution agreements with major pharmaceutical producers, such as Kelun Pharmaceutical, to tap into the growing Chinese healthcare market. Lakeside Holding Ltd (NASDAQ:LSH) is focusing on providing high-volume, customized logistics solutions, which differentiates it from competitors and helps maintain competitiveness in the cross-border freight market. Lakeside Holding Ltd (NASDAQ:LSH) reported a decrease in total revenues to $11.48 million for the nine months ended March 31, 2025, down from $13.53 million in the same period last year. The company's cross-...

ITASCA, IL, May 15, 2025 (GLOBE NEWSWIRE) -- Lakeside Holding Limited (“Lakeside” or the “Company”) (Nasdaq: LSH), a U.S.-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market operating through two specialized subsidiaries—American Bear Logistics and Hupan Pharmaceutical (Hubei) Co., Ltd., today announced financial results for its fiscal 2025 third quarter and nine months ended March 31, 2025. Management Commentary "The third quarter and first nine months of fiscal 2025 presented a dynamic environment for Lakeside," commented Henry Liu, Chief Executive Officer. "While our established cross-border freight solutions experienced revenue declines compared to the prior year, primarily due to shifts in global shipping demands and pricing pressures, we are encouraged by the initial contributions from our new pharmaceutical distribution segment following the Hupan Pharmaceutical acquisition. Our strategic objectives remain clear: expand our footprint in China's pharmaceutical distribution market, where significant growth opportunities exist, while continuing to optimize our cross-border logistics services. We are actively integrating Hupan Pharmaceutical into our operations to leverage synergies between business segments. Despite challenging market conditions in the freight sector, we remain committed to diversifying revenue streams and investing in high-growth areas. We believe our strategic focus on the Asia-Pacific market, coupled with our expansion into the pharmaceutical sector, positions Lakeside for long-term shareholder value creation." Highlights for the Nine Months Ended March 31, 2025, and Recent Developments: Successful Initial Public Offering (IPO): On July 1, 2024, the Company successfully closed its IPO of 1,500,000 shares of common stock at $4.50 per share, raising aggregate gross proceeds of approximately $6.75 million (net proceeds of approximately $5.4 million after deducting underwriting discounts, commissions, and other offering expenses). This milestone provided significant capital to support the Company’s growth strategies and operational expansion. Acquisition of Hupan Pharmaceutical: On November 21, 2024, Lakeside completed the acquisition of Hupan Pharmaceutical (Hubei) Co., Ltd. (“Hupan Pharmaceutical”), marking its entry into the medical logistics and pharmaceutical distribution sector in China....